Developer docs
API playgroundTry for free, no card

Search company profiles

Adium

Full company profile

uuid000au6v

Namestring
Adium
Legal namestring
Adium Pharma S.A.
Websiteurl
adiumpharma.com
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Adium Pharma S.A. is a privately held Uruguayan pharmaceutical company headquartered in Montevideo that operates as a regional commercialization and distribution partner for global innovative pharmaceutical and biotechnology companies across Latin America. With more than 50 years of operating history and own operations in 18 Latin American countries, Adium markets and distributes a broad portfolio of therapeutics spanning 15 areas including cardiology, diabetes, oncology, neurology, hematology, rare diseases, immunology, and psychiatry. The company's revenue model is built primarily on licensing and distribution agreements with originator companies (Pfizer, Eli Lilly, Amgen, Regeneron, Moderna, Astellas, PharmaMar, Y-mAbs, Jazz Pharmaceuticals, Debiopharm), under which Adium provides regulatory registration, market access, sales force deployment, medical affairs, pharmacovigilance, and supply chain services. Notable recent commercial wins include exclusive distribution of Regeneron's cemiplimab (LIBTAYO®) in Brazil and a COVID-19 vaccine distribution partnership with Moderna across the region.

Adium's underlying technology stack centers on pharmaceutical manufacturing executed under a Quality by Design approach, with production plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay holding certifications from local and international regulatory authorities. The R&D function employs pharmacists, chemists, biochemists, research engineers, and process technicians to support formulation and clinical studies. Manufacturing services are offered both for Adium's own portfolio and for partner products, including secondary packaging. A documented Pharmacovigilance System governs patient safety processes across the organization. The company also operates Vertismed, a digital platform for medical-scientific content targeted at healthcare professionals.

The go-to-market is sales-led and B2B in nature: Adium serves as the regional gateway for global innovators, combining a high-impact sales force specialized in high-tech products with Market Access teams (for pricing and reimbursement), Medical Affairs teams (for continuous medical education), and compliance infrastructure. Pricing is not publicly disclosed and follows regional regulatory frameworks. The company targets healthcare professionals and patients across Latin America through its 18-country commercial footprint, supported by a LinkedIn presence and the Vertismed platform for medical engagement.

Short descriptiontext

Adium Pharma S.A. is a Uruguay-headquartered pharmaceutical company that commercializes and distributes innovative therapeutics from global pharma partners across 18 Latin American countries, spanning 15 therapeutic areas including oncology, cardiology, and rare diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMontevideo, Uruguay
HQ citystring
Montevideo
HQ countrystring
Uruguay
HQ regionstring
Latin America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution, pharmaceutical manufacturing, therapeutic products, biotech commercialization, medical affairs services
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Distribution and Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Distribution and Commercialization
TypeLicensing Royalties
Description

Adium generates revenue by partnering with global innovative pharmaceutical and biotechnology companies to promote and distribute their products across Latin America. The company operates as a commercial partner, leveraging its regional presence, regulatory expertise, supply chain capabilities, and sales force to commercialize products from licensors throughout the region.

adiumpharma.com
2Manufacturing Services
TypeProfessional Services
Description

Secondary packaging plants and production capabilities across multiple Latin American countries, serving both own portfolio and partner products

adiumpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Vertismed
Description

A platform for medical-scientific content with more than 40 articles, 21 3D objects, and interactive books.

adiumpharma.com
Core offering1 text field

Adium is a pharmaceutical company operating in 18 Latin American countries that manufactures, distributes, and commercializes a broad portfolio of therapeutic products across 15 specialty areas including cardiology, diabetes, oncology, neurology, and rare diseases. The company serves as the regional commercial partner and 'gateway to innovation' for global pharmaceutical and biotechnology companies seeking to expand into Latin America, providing regulatory, supply chain, manufacturing, sales force, market access, and pharmacovigilance capabilities. It also operates its own manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Broad therapeutic portfolio covering 14+ specialty areas
Product overview1 text field

Adium is a leading pharmaceutical company in Latin America with over 50 years of experience, offering a broad portfolio of high-quality therapeutic solutions across 15 therapeutic areas including Cardiology, Diabetes, Oncology, Neurology, Hematology, and Rare Diseases. The company operates as both a pharmaceutical product provider and a regional partner of choice for global biotech and innovative companies seeking to expand into Latin America. Adium's portfolio includes products for pain treatment, obesity, osteoporosis, gynecology, gastroenterology, immunology, psychiatry, and urology. Beyond product commercialization, Adium provides integrated services including manufacturing (with plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay), research and development, pharmacovigilance, regulatory support, supply chain, and market access capabilities. The company also offers Vertismed, a medical-scientific content platform.

Product and service19 records
1Cardiology Products
CategoryTherapeutic Area
Description

Pharmaceutical products for the treatment of hypertension, hypercholesterolemia, and anticoagulation targeting cardiovascular diseases, the leading cause of death in Latin America.

2Diabetes Products
CategoryTherapeutic Area
Description

Pharmaceutical products for the treatment of Type I and Type II Diabetes, addressing one of the main causes of death and disability in Latin America.

3Oncology Products
CategoryTherapeutic Area
Description

Broad portfolio of medications aimed at combating various types of cancer affecting lung, breast, pancreas, or bile ducts.

4Rare Diseases Products
CategoryTherapeutic Area
Description

Medications to treat diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis.

5Neurology Products
CategoryTherapeutic Area
Description

Modern and effective molecules for treatment of patients with Alzheimer's disease, epilepsy, and Parkinson's.

6Pain Treatment Products
CategoryTherapeutic Area
Description

Leading molecules for acute and chronic pain treatment aimed at improving quality of life by reducing patient suffering.

7Hematology Products
CategoryTherapeutic Area
Description

Biotechnology-derived innovative molecules to treat blood diseases including anemia, thrombopathies, lymphomas, hemophilia, and leukemia.

8Immunology Products
CategoryTherapeutic Area
Description

Drugs with target molecules for treatment of immune diseases including rheumatoid arthritis, multiple sclerosis, and myasthenia gravis.

9Gynecology Products
CategoryTherapeutic Area
Description

Wide range of contraceptives, both oral and devices, focusing on women's health through the study of the female reproductive system.

10Obesity Treatment Products
CategoryTherapeutic Area
Description

Different molecules and combinations to help achieve desired goals in obesity treatment, addressing the complex disease of excessive body fat.

11Osteoporosis Products
CategoryTherapeutic Area
Description

Innovative portfolio for treatment and prevention of osteoporosis and osteopenia, reducing fracture risks for older adults.

12Psychiatry Products
CategoryTherapeutic Area
Description

Multiple therapeutic alternatives for the treatment of psychiatric conditions manifesting as disturbances in thought, emotions, or behavior.

13Urology Products
CategoryTherapeutic Area
Description

Innovative medications for overactive bladder, benign prostatic hyperplasia, and erectile dysfunction.

14Osteoarticular Products
CategoryTherapeutic Area
Description

Medications and devices for degenerative joint disease including successful combinations and viscosupplementation devices.

15Gastroenterology Products
CategoryTherapeutic Area
Description

Effective molecules for the treatment of peptic ulcer disease and irritable bowel syndrome caused by bacteria, parasites, viruses, or certain foods.

16Manufacturing Services
CategoryManufacturing Services
Description

Production centers in Argentina, Paraguay, Brazil, Mexico, and Uruguay governed by highest standards of quality and efficiency, equipped with state-of-the-art technology and holding certifications from prominent local and international regulatory authorities.

17Research and Development Services
CategoryR&D Services
Description

Quality by Design approach in product development with multidisciplinary team including pharmacists, chemists, biochemists, research engineers, and process technicians, investing in clinical studies to support production of safe and effective medicines.

18Pharmacovigilance Services
CategoryCompliance Services
Description

Documented processes, activities, and procedures ensuring functioning of Pharmacovigilance System for patient safety.

19Vertismed
CategoryMedical Education Platform
Description

Medical-scientific content platform featuring more than 40 articles, 21 3D objects, and interactive books for healthcare professionals.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Adium announced exclusive distribution agreement with Regeneron to commercialize CEMIPLIMAB (LIBTAYO®) in Brazil, demonstrating Adium's role as a key distribution partner for global innovative pharmaceutical products in Latin America.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Adium reached an important agreement with Moderna Inc. to collaborate in the distribution and commercialization of COVID-19 vaccines in Latin America.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Laboratorios Roemmers
TypeDirect peer
Description

Argentine pharmaceutical group with broad presence across Latin America in cardiology, neurology, and other specialty areas, with own manufacturing. Comparable to Adium as a Southern Cone-anchored LatAm pharma with multi-country distribution.

TypeRegional player
Description

Brazilian pharmaceutical company with cardiovascular and specialty focus expanding across Latin America. Comparable as a regional pharma with branded specialty portfolio in cardiology, an area where Adium is also heavily exposed.

TypeDirect peer
Description

Argentine pharmaceutical group with operations throughout Latin America in cardiology, central nervous system, and other specialty areas. Comparable as a Southern Cone multi-country pharma with partner-distribution model.

TypeBroad incumbent
Description

Global pharmaceutical major with deep own operations across Latin America in cardiology, women's health, and specialty. Comparable as a multinational with direct LatAm commercialization capabilities that competes with and also partners with regional players like Adium.

TypeBroad incumbent
Description

Global generics and specialty pharmaceutical company with established commercial presence in Latin America. Comparable as a partner/distributor model across multiple LatAm countries in specialty and generics.

TypeDirect peer
Description

Multi-Latin pharmaceutical company (now part of Sanofi) historically focused on generics and specialty across Latin America. Comparable to Adium in its pan-regional LatAm pharmaceutical distribution model.

7Eurofarma Laboratórios
TypeDirect peer
Description

Brazilian-headquartered pharmaceutical company with multi-country Latin American presence, manufacturing footprint, and portfolio spanning branded specialty, generics, and OTC. Directly comparable to Adium as a regional LatAm pharma platform with own manufacturing and partner distribution.

TypeDirect peer
Description

Brazilian pharmaceutical company with growing presence across Latin America across prescription, generics, and OTC categories, with own manufacturing plants. Comparable in therapeutic breadth and LatAm multi-country footprint.

TypeRegional player
Description

Brazilian pharmaceutical leader with extensive generics and branded portfolio and growing Latin American reach. Comparable to Adium as a regional LatAm pharma, though primarily Brazil-anchored.

TypeRegional player
Description

India-headquartered pharmaceutical company with established Latin American commercial footprint in specialty, dermatology, and respiratory. Comparable as a regional pharma expanding via licensing/distribution partnerships in LatAm.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adium

Pharmaceutical Distribution and Manufacturingadiumpharma.com

Adium Pharma S.A. is a Uruguay-headquartered pharmaceutical company that commercializes and distributes innovative therapeutics from global pharma partners across 18 Latin American countries, spanning 15 therapeutic areas including oncology, cardiology, and rare diseases.

What Adium does

Adium Pharma S.A. is a privately held Uruguayan pharmaceutical company headquartered in Montevideo that operates as a regional commercialization and distribution partner for global innovative pharmaceutical and biotechnology companies across Latin America. With more than 50 years of operating history and own operations in 18 Latin American countries, Adium markets and distributes a broad portfolio of therapeutics spanning 15 areas including cardiology, diabetes, oncology, neurology, hematology, rare diseases, immunology, and psychiatry. The company's revenue model is built primarily on licensing and distribution agreements with originator companies (Pfizer, Eli Lilly, Amgen, Regeneron, Moderna, Astellas, PharmaMar, Y-mAbs, Jazz Pharmaceuticals, Debiopharm), under which Adium provides regulatory registration, market access, sales force deployment, medical affairs, pharmacovigilance, and supply chain services. Notable recent commercial wins include exclusive distribution of Regeneron's cemiplimab (LIBTAYO®) in Brazil and a COVID-19 vaccine distribution partnership with Moderna across the region.

Adium's underlying technology stack centers on pharmaceutical manufacturing executed under a Quality by Design approach, with production plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay holding certifications from local and international regulatory authorities. The R&D function employs pharmacists, chemists, biochemists, research engineers, and process technicians to support formulation and clinical studies. Manufacturing services are offered both for Adium's own portfolio and for partner products, including secondary packaging. A documented Pharmacovigilance System governs patient safety processes across the organization. The company also operates Vertismed, a digital platform for medical-scientific content targeted at healthcare professionals.

The go-to-market is sales-led and B2B in nature: Adium serves as the regional gateway for global innovators, combining a high-impact sales force specialized in high-tech products with Market Access teams (for pricing and reimbursement), Medical Affairs teams (for continuous medical education), and compliance infrastructure. Pricing is not publicly disclosed and follows regional regulatory frameworks. The company targets healthcare professionals and patients across Latin America through its 18-country commercial footprint, supported by a LinkedIn presence and the Vertismed platform for medical engagement.

Adium firmographics

Firmographics
Name
Adium
Legal name
Adium Pharma S.A.
Website
https://adiumpharma.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Adium Pharma S.A. is a Uruguay-headquartered pharmaceutical company that commercializes and distributes innovative therapeutics from global pharma partners across 18 Latin American countries, spanning 15 therapeutic areas including oncology, cardiology, and rare diseases.
Ownership category
akta.pro rank

Adium industry classification

Industry
Product category
Pharmaceutical Distribution and Manufacturing
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Pharmaceutical distribution
  • Pharmaceutical manufacturing
  • Therapeutic products
  • Biotech commercialization
  • Medical affairs services

Where Adium is headquartered

Location

Headquarters

HQ city
Montevideo
HQ country
Uruguay
HQ region
Latin America

Offices5 records

Markets served

Adium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Distribution and Commercialization: Adium generates revenue by partnering with global innovative pharmaceutical and biotechnology companies to promote and distribute their products across Latin America. The company operates as a commercial partner, leveraging its regional presence, regulatory expertise, supply chain capabilities, and sales force to commercialize products from licensors throughout the region.
  2. Manufacturing Services: Secondary packaging plants and production capabilities across multiple Latin American countries, serving both own portfolio and partner products

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Adium product offering

Product offering

Core offering

Adium is a pharmaceutical company operating in 18 Latin American countries that manufactures, distributes, and commercializes a broad portfolio of therapeutic products across 15 specialty areas including cardiology, diabetes, oncology, neurology, and rare diseases. The company serves as the regional commercial partner and 'gateway to innovation' for global pharmaceutical and biotechnology companies seeking to expand into Latin America, providing regulatory, supply chain, manufacturing, sales force, market access, and pharmacovigilance capabilities. It also operates its own manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay.

Product overview

Adium is a leading pharmaceutical company in Latin America with over 50 years of experience, offering a broad portfolio of high-quality therapeutic solutions across 15 therapeutic areas including Cardiology, Diabetes, Oncology, Neurology, Hematology, and Rare Diseases. The company operates as both a pharmaceutical product provider and a regional partner of choice for global biotech and innovative companies seeking to expand into Latin America. Adium's portfolio includes products for pain treatment, obesity, osteoporosis, gynecology, gastroenterology, immunology, psychiatry, and urology. Beyond product commercialization, Adium provides integrated services including manufacturing (with plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay), research and development, pharmacovigilance, regulatory support, supply chain, and market access capabilities. The company also offers Vertismed, a medical-scientific content platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Vertismed: A platform for medical-scientific content with more than 40 articles, 21 3D objects, and interactive books.

Products and services

  • Cardiology Products Pharmaceutical products for the treatment of hypertension, hypercholesterolemia, and anticoagulation targeting cardiovascular diseases, the leading cause of death in Latin America.
  • Diabetes Products Pharmaceutical products for the treatment of Type I and Type II Diabetes, addressing one of the main causes of death and disability in Latin America.
  • Oncology Products Broad portfolio of medications aimed at combating various types of cancer affecting lung, breast, pancreas, or bile ducts.
  • Rare Diseases Products Medications to treat diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis.
  • Neurology Products Modern and effective molecules for treatment of patients with Alzheimer's disease, epilepsy, and Parkinson's.
  • Pain Treatment Products Leading molecules for acute and chronic pain treatment aimed at improving quality of life by reducing patient suffering.
  • Hematology Products Biotechnology-derived innovative molecules to treat blood diseases including anemia, thrombopathies, lymphomas, hemophilia, and leukemia.
  • Immunology Products Drugs with target molecules for treatment of immune diseases including rheumatoid arthritis, multiple sclerosis, and myasthenia gravis.
  • Gynecology Products Wide range of contraceptives, both oral and devices, focusing on women's health through the study of the female reproductive system.
  • Obesity Treatment Products Different molecules and combinations to help achieve desired goals in obesity treatment, addressing the complex disease of excessive body fat.
  • Osteoporosis Products Innovative portfolio for treatment and prevention of osteoporosis and osteopenia, reducing fracture risks for older adults.
  • Psychiatry Products Multiple therapeutic alternatives for the treatment of psychiatric conditions manifesting as disturbances in thought, emotions, or behavior.
  • Urology Products Innovative medications for overactive bladder, benign prostatic hyperplasia, and erectile dysfunction.
  • Osteoarticular Products Medications and devices for degenerative joint disease including successful combinations and viscosupplementation devices.
  • Gastroenterology Products Effective molecules for the treatment of peptic ulcer disease and irritable bowel syndrome caused by bacteria, parasites, viruses, or certain foods.
  • Manufacturing Services Production centers in Argentina, Paraguay, Brazil, Mexico, and Uruguay governed by highest standards of quality and efficiency, equipped with state-of-the-art technology and holding certifications from prominent local and international regulatory authorities.
  • Research and Development Services Quality by Design approach in product development with multidisciplinary team including pharmacists, chemists, biochemists, research engineers, and process technicians, investing in clinical studies to support production of safe and effective medicines.
  • Pharmacovigilance Services Documented processes, activities, and procedures ensuring functioning of Pharmacovigilance System for patient safety.
  • Vertismed Medical-scientific content platform featuring more than 40 articles, 21 3D objects, and interactive books for healthcare professionals.

Quantifiable outcome

  • Broad therapeutic portfolio covering 14+ specialty areas

Companies that use Adium

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Adium technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Adium partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core.

  • RegeneroncoreChannel Partner/ Reseller/ DistributorAdium announced exclusive distribution agreement with Regeneron to commercialize CEMIPLIMAB (LIBTAYO®) in Brazil, demonstrating Adium's role as a key distribution partner for global innovative pharmaceutical products in Latin America.
  • Moderna Inc.coreChannel Partner/ Reseller/ DistributorAdium reached an important agreement with Moderna Inc. to collaborate in the distribution and commercialization of COVID-19 vaccines in Latin America.
  • Eli LillycoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • AmgencoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • PfizercoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • DebiopharmcoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • AstellascoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • PharmaMarcoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • Y-mAbscoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
  • Jazz PharmaceuticalscoreChannel Partner/ Reseller/ DistributorLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Adium competitors and assessment

Company assessment

Direct peers

  • Laboratorios Roemmers: Argentine pharmaceutical group with broad presence across Latin America in cardiology, neurology, and other specialty areas, with own manufacturing. Comparable to Adium as a Southern Cone-anchored LatAm pharma with multi-country distribution.
  • Laboratorios Bagó: Argentine pharmaceutical group with operations throughout Latin America in cardiology, central nervous system, and other specialty areas. Comparable as a Southern Cone multi-country pharma with partner-distribution model.
  • Genfar (Sanofi): Multi-Latin pharmaceutical company (now part of Sanofi) historically focused on generics and specialty across Latin America. Comparable to Adium in its pan-regional LatAm pharmaceutical distribution model.
  • Eurofarma Laboratórios: Brazilian-headquartered pharmaceutical company with multi-country Latin American presence, manufacturing footprint, and portfolio spanning branded specialty, generics, and OTC. Directly comparable to Adium as a regional LatAm pharma platform with own manufacturing and partner distribution.
  • Aché Laboratórios Farmacêuticos: Brazilian pharmaceutical company with growing presence across Latin America across prescription, generics, and OTC categories, with own manufacturing plants. Comparable in therapeutic breadth and LatAm multi-country footprint.

Regional players

  • Biolab Farmacêutica: Brazilian pharmaceutical company with cardiovascular and specialty focus expanding across Latin America. Comparable as a regional pharma with branded specialty portfolio in cardiology, an area where Adium is also heavily exposed.
  • EMS Pharma: Brazilian pharmaceutical leader with extensive generics and branded portfolio and growing Latin American reach. Comparable to Adium as a regional LatAm pharma, though primarily Brazil-anchored.
  • Glenmark Pharmaceuticals (LatAm): India-headquartered pharmaceutical company with established Latin American commercial footprint in specialty, dermatology, and respiratory. Comparable as a regional pharma expanding via licensing/distribution partnerships in LatAm.

Broad incumbents

  • Bayer (Pharmaceuticals, LatAm): Global pharmaceutical major with deep own operations across Latin America in cardiology, women's health, and specialty. Comparable as a multinational with direct LatAm commercialization capabilities that competes with and also partners with regional players like Adium.
  • Teva Pharmaceutical (LatAm): Global generics and specialty pharmaceutical company with established commercial presence in Latin America. Comparable as a partner/distributor model across multiple LatAm countries in specialty and generics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Adium social profiles

Digital presence

Adium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adium leadership team

Management profile

Number of profiles

Adium funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adium

What does Adium do?

Adium is a pharmaceutical company operating in 18 Latin American countries that manufactures, distributes, and commercializes a broad portfolio of therapeutic products across 15 specialty areas including cardiology, diabetes, oncology, neurology, and rare diseases. The company serves as the regional commercial partner and 'gateway to innovation' for global pharmaceutical and biotechnology companies seeking to expand into Latin America, providing regulatory, supply chain, manufacturing, sales force, market access, and pharmacovigilance capabilities. It also operates its own manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay.

Is Adium a public or private company?

Adium is a private company. It is classified as unknown and is currently operating.

When was Adium founded?

Adium was founded in 1970. It employs 1,001 to 5,000 people.

Where is Adium based?

Adium is headquartered in Montevideo, Uruguay, in the Latin America region.

How does Adium make money?

Two revenue lines are on record. Pharmaceutical Distribution and Commercialization is the primary driver. The others are manufacturing Services.

Who are Adium's main competitors?

Direct peers on record are Laboratorios Roemmers, Laboratorios Bagó, Genfar (Sanofi), Eurofarma Laboratórios and Aché Laboratórios Farmacêuticos. Regional players are Biolab Farmacêutica, EMS Pharma and Glenmark Pharmaceuticals (LatAm). Broad incumbents are Bayer (Pharmaceuticals, LatAm) and Teva Pharmaceutical (LatAm).

Does Adium have an API?

No public API is recorded for Adium.

What industry is Adium in?

Adium's product category is Pharmaceutical Distribution and Manufacturing. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mexico Business NewsBuilding A Competitive Presence Through High-Value TreatmentsAdium holds a top-three position in Mexico's private ethical pharmaceutical market, having risen from 19th in a decade. It plans to enter the OTC market with products like Contumax and aims for double-digit annual growth through 2030. The company also leverages licensing partnerships across 18 Latin American countries.PR NewswireASOFARMA CENTROAMÉRICA Y EL CARIBE, A TRAVÉS DE SU CASA MATRIZ ADIUM, LLEGA A UN IMPORTANTE ACUERDO CON MODERNA INC. PARA COLABORAR EN LA DISTRIBUCIÓN Y COMERCIALIZACIÓN DE VACUNAS CONTRA EL COVID 19ASOFARMA Centroamérica y el Caribe, a través de su empresa matriz ADIUM, firmó un acuerdo de colaboración con Moderna Inc. para la distribución y comercialización de la vacuna SPIKEVAX contra la COVID-19 en la región centroamericana y del Caribe. El acuerdo, anunciado el 23 de febrero de 2022 desde Ciudad de Panamá, establece que ASOFARMA gestionará contratos de suministro, registro de vacunas, farmacovigilancia, formación médica, asuntos gubernamentales y comercialización para facilitar el acceso a SPIKEVAX en la región. Con esta alianza, Moderna se incorpora al portafolio de empresas farmacéuticas y biotecnológicas internacionales representadas por ASOFARMA durante más de veinte años.GlobeNewswireY-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin AmericaY-mAbs entered an exclusive distribution agreement with Adium Pharma to distribute DANYELZA and omburtamab in Latin America. DANYELZA is FDA-approved for neuroblastoma, and omburtamab's MAA was submitted to the EMA in April 2021. Financial terms were not disclosed.